Cardiff Oncology Data Suggests Potential Synergy with Roche's T-DXd
Event summary
- Cardiff Oncology will present preclinical data at the 2026 AACR Annual Meeting on April 19, 2026.
- The data focuses on onvansertib, a PLK1 inhibitor, in combination with trastuzumab deruxtecan (T-DXd).
- Findings indicate onvansertib enhanced T-DXd’s activity and reversed resistance in HER2-low breast cancer models.
- Onvansertib is currently in Phase 2 clinical development for RAS-mutated metastatic colorectal cancer (mCRC).
The big picture
The combination of targeted therapies like onvansertib with existing antibody-drug conjugates (ADCs) like T-DXd represents a growing trend in oncology, aiming to overcome resistance and improve patient outcomes. This data suggests a potential avenue for Cardiff Oncology to expand its pipeline and potentially partner with larger pharmaceutical companies. The success of this combination will hinge on demonstrating a clinically meaningful benefit and navigating the complexities of co-commercialization or licensing agreements.
What we're watching
- Clinical Validation
- The upcoming AACR presentation's data will be crucial in determining if the preclinical synergy between onvansertib and T-DXd translates to meaningful clinical benefit in human trials, particularly given the challenges in HER2-low breast cancer.
- Commercial Implications
- How Cardiff Oncology navigates potential partnerships or licensing agreements with Roche, the manufacturer of T-DXd, will significantly impact the commercial viability of onvansertib in HER2-low breast cancer.
- Pipeline Expansion
- The pace at which Cardiff Oncology expands onvansertib’s investigation into other cancers beyond its lead indication of mCRC will depend on the success of ongoing investigator-initiated trials and the availability of funding.
Related topics